ArticleAging and disease2022
Stem Cell Transplantation for Parkinson's Disease: Current Challenges and Perspectives.
Article in Aging and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Review
- Synergy between stem cell therapy and brain-derived neurotrophic factor (BDNF) in Parkinson's disease: a mini-review of combined neuroregenerative strategies.Chinese neurosurgical journal · 2025Review
- HucMSCs-derived Exosomes Protect Against 6-hydroxydopamineinduced Parkinson's Disease in Rats by Inhibiting Caspase-3 Expression and Suppressing Apoptosis.Current stem cell research & therapy · 2025Article
- Astrocyte-Derived Extracellular Vesicles for Ischemic Stroke: Therapeutic Potential and Prospective.Aging and disease · 2024Review
- Some Novel Therapies in Parkinson's Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature.Biomedicines · 2024Review
- Simultaneous treatment with cells and rosemary extract ameliorates 6-OHDA-induced toxicity in the hippocampus of mice.Journal of advanced pharmaceutical technology & researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease is the second most common form of neurodegeneration, and it poses a major threat to the quality of life of older adults. Stem cell transplantation, which has attracted widespread attention from researchers, is a new treatment that is demonstrating excellent potential for treating Parkinson's disease. This paper introduces the advantages, disadvantages, and current research on the progress of using stem cells for Parkinson's disease; briefly describes the strategies for controlling the differentiation of stem cells into dopaminergic neurons in vitro; highlights how transplanted cells improve the loss of dopaminergic neurons by interacting with the inflammatory microenvironment in the brain; and proposes that future stem cell research focus on finely regulating the signal pathways that influence the directed differentiation of dopaminergic neurons to maintain an appropriate balance between the modulatory factors that affect the inflammatory microenvironment and clarify the interaction between neurons and neuroglia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.